Patient P-02299
Synthetic patientMETA-24 · Day 113 · 25–34 · F · baseline S14Steering view · 3DOpen companion preview
Therapy response
Stable
Tolerance
Improving
GI state
Deteriorating
Inflammatory state
Deteriorating
Nutritional resilience
Stable
Discontinuation risk
66%
Trajectory
Baseline → today → 30-day prediction · hover a day for signals and eventssolid = observed · dashed = predicted
- Day 0 META-24 started — Baseline state S14
- Day 13 Trajectory diverged from prediction — Observed response fell below the model's expected path.
- Day 68 SC-12 recommended — Supportive Compound SC-12
- Day 69 Patient accepted — Started SC-12 in the companion
- Day 71 GI-04 recommended — GI Support Protocol GI-04
- Day 72 Patient accepted — Started GI-04 in the companion
- Day 75 No meaningful change — Supportive Compound SC-12
- Day 80 GI symptom burden −36% vs expected — GI Support Protocol GI-04
- Day 86 Tolerance state changed — Unstable → Improving
- Day 92 ME-01 recommended — Monitoring Escalation ME-01
- Day 93 Patient accepted — Started ME-01 in the companion
- Day 96 Deterioration detected before clinical escalation — Monitoring Escalation ME-01
What changed?
Trajectory began diverging from predicted response on Day 13.
Primary contributors, last 14 days
- Treatment adherence-18
- GI instability+8
- Inflammatory activity+6
- Toxicity-4
- Nutritional resilience+2
What helped?
- Supportive Compound SC-12Day 68Result: no meaningful change
- GI Support Protocol GI-04Day 71Result: symptom burden −36%
- Monitoring Escalation ME-01Day 92Result: deterioration detected before clinical escalation
LIFE OS recommendation
Clinician Review CR-01
76%
probability of meaningful tolerance improvement
- 284 similar trajectories
- 100% showed improvement
- median effect visible after 5 days
Daily trackers
Molecule settingsThe trackers this program marks as important, last 14 days vs the 14 before.
Active minutes
Wearable20 min
worsening · -5.2 vs previous 14 d
Sleep duration
Wearable5.5 h
worsening · -0.3 vs previous 14 d
Energy level
Daily log3.8/10
worsening · -0.7 vs previous 14 d
Steps
Wearable1,866
worsening · -187 vs previous 14 d
GI burden
Companion49.3/100
worsening · +9.5 vs previous 14 d
Adherence
Companion62.9 %
worsening · -20.6 vs previous 14 d
Sleep quality
Wearable23.3/100
worsening · -6.0 vs previous 14 d
Glucose, CGM daily mean
CGM137 mg/dL
stable · +3.6 vs previous 14 d
This trajectory is decaying — what would help, what would not
Steering view →Heading towards failing · 43 from the failing basin, 47 from restoration.
Would help
- NP-02 Dietary Support Protocol63% improved among 24 similar · onset 10 d · confidence 64%
- DT-01 Dosing / Timing Recommendation86% improved among 7 similar · onset 5 d · confidence 64%
- CR-01 Clinician Review100% improved among 6 similar · onset 5 d · confidence 64%
- More proteinGI -5.2 next day on high-intake days · n 15
Would not help
- SC-12 Supportive Compoundalready tried, no meaningful change
- Keep fat lowGI +4.5 next day on high-intake days · n 28
- Keep simple carbs lowGI +3.6 next day on high-intake days · n 19
- Keep fibre lowGI +3.4 next day on high-intake days · n 18
State influencers · digestive
Next-day GI change on high-intake vs low-intake days, last 60 days. Attribution from this patient's own log; sensitivity set by their biology.
- Protein-5.2supporter · 95%
- Dietary fat load+4.5detractor · 95%
- Simple carbohydrates+3.6detractor · 80%
- Insoluble fibre+3.4detractor · 78%
- Ultra-processed food+3.4detractor · 91%
- Alcohol+1.2no signal · 20%
- Histamine load+1.1no signal · 22%
- Caffeine+0.3no signal · 15%
Biological layers
Which pathways look influenced, and by which layer of this person's biology.
Pathways under pressure
- Butyrate / short-chain fatty acid production ↓80
- MicrobiomeButyrate capacity 25/100
- MicrobiomeF. prausnitzii depleted
- Daily logFibre intake low in recent food logs
- Autonomic recovery ↑65
- WearableResting HR 75 bpm
- Wearable1,866 steps/day
- WearableShort sleep window
- Inflammatory signalling ↑50
- DNAIL6 -174 variant raises baseline inflammatory tone
- BloodInflammatory load index 51
- Mucosal barrier integrity ↓30
- Daily logGI symptom score 49 and rising
- WearableSleep 5.5 h, below personal baseline
DNA
Fictional pharmacogenomic panel
- IL6 -174 G/CHigher inflammatory tone
- CYP2D6 Normal metabolizerExpected exposure
- GLP1R rs6923761 AAltered receptor sensitivity
Microbiome
Shannon diversity 2.8 · butyrate capacity 25/100
- Akkermansia muciniphilaNormal
- Faecalibacterium prausnitziiLow
- Bacteroides fragilisNormal
- Bifidobacterium longumNormal
- EnterobacteriaceaeHigh
Wearable, last 14 days
daily evolution fed into the runtime
- HRV
- 56 ms
- Sleep
- 6.0 h
- Steps
- 2,777
- Resting HR
- 72 bpm
Daily log: GI score 49, nutritional resilience 45, adherence 63.
What this patient sees in NostraAI
The content that steers the trajectory: what to eat, what to do, what to take.
What to eat
- Prepare a plain, low-fat pasta or rice meal and note how it feels afterwards
- Choose a freshly cooked, lean protein; avoid frying, rich sauces and leftovers for now
- Add one soluble-fibre source (oats, cooked carrots, banana) to breakfast
- Eat slowly and stop at comfortable fullness — smaller volume, more often
What to do
- Track each bowel movement today: time, stool form, urgency, overnight waking
- A 15-minute walk after lunch
- Protect a 7.5-hour sleep window; screens off 30 minutes before
- Keep hydration steady: small amounts through the day rather than large volumes at once
What to take
- Take the dose at the same time relative to your evening meal
- Electrolyte solution, one sachet after any loose stool
- Fictional demo item: oral nutrition supplement with lunch
284 biologically similar trajectories
Black: this patient. Green: similar patients whose intervention worked. Orange: similar patients where it did not.
| Patient | Similarity | Baseline | Intervention | Outcome | Response today |
|---|---|---|---|---|---|
| P-02483 | 29% | S06 | BR-03 | no change | 64 |
| P-02280 | 25% | S07 | BR-03 | no change | 50 |
| P-02054 | 31% | S01 | CR-01 | improved | 57 |
| P-02233 | 31% | S16 | CR-01 | improved | 66 |
| P-02154 | 30% | S16 | CR-01 | improved | 57 |
| P-02009 | 29% | S08 | CR-01 | improved | 64 |
| P-02025 | 26% | S15 | CR-01 | improved | 61 |
| P-02151 | 26% | S04 | CR-01 | improved | 49 |
| P-02491 | 29% | S09 | DT-01 | no change | 65 |
| P-02274 | 26% | S15 | DT-01 | improved | 50 |
| P-02395 | 26% | S12 | DT-01 | improved | 57 |
| P-02462 | 26% | S12 | DT-01 | improved | 65 |